Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Filing date: November 12, 2020; event date: November 11, 2020. The filing reports corporate governance changes under Item 5.02 and furnishes a related press release under Regulation FD. It does not report quarterly or annual financial results.
Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. is a Delaware corporation whose common stock trades on Nasdaq under the symbol HRMY. The company reported an increase in the size of its Board of Directors from seven to nine members.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or financial guidance.
- No financial statements or other quantitative operating metrics are included.
Material Changes and Governance Actions
- Mark Graf was appointed as a Class I director effective November 11, 2020. His term extends through the 2021 annual meeting of stockholders, unless he leaves office earlier.
- Eric Motley was appointed as a Class II director effective November 11, 2020. His term extends through the 2022 annual meeting of stockholders, unless he leaves office earlier.
- Mr. Graf was appointed to the Audit Committee and was determined to be independent under Nasdaq standards and the heightened independence requirements applicable to Audit Committee members.
- Mr. Motley was determined to be independent under Nasdaq standards.
- Both directors will receive compensation under the company’s non-employee director compensation program and will enter into the company’s standard director indemnification agreement.
Management Commentary, Risks, and Unusual Items
- The company cited Mr. Graf’s financial management, capital analysis, business, and risk-management expertise as the basis for his appointment.
- The company cited Mr. Motley’s management, organizational, and governance experience as the basis for his appointment.
- The filing states that neither appointment resulted from an arrangement or understanding with another person, and that neither director has reportable family relationships or related-party transactions.
- No business outlook, contingencies, litigation developments, or unusual financial items are disclosed.
- Exhibit 99.1 is a furnished press release and generally is not deemed filed for liability purposes under Section 18 of the Exchange Act, except where specifically incorporated by reference.
Investor Verification Points
- Verify the directors’ committee assignments, independence determinations, and terms in subsequent proxy statements.
- Review the company’s director compensation program and indemnification agreement for the applicable economic terms.
- Consult subsequent filings for any changes in board composition or committee membership.
- Use the company’s periodic reports, rather than this 8-K, to assess revenue, profitability, cash flow, liquidity, debt, and operating outlook.